Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Ophthalmol. 2006 Dec;142(6):1054-6. Epub 2006 Aug 2.

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

Author information

  • 1Department of Ophthalmology, University of Bern, Inselspital, Bern, Switzerland. milko.lliev@insel.ch

Abstract

PURPOSE:

To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin).

DESIGN:

Retrospective interventional case series.

METHODS:

Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.

RESULTS:

IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.

CONCLUSION:

IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.

PMID:
17157590
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk